

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Beyond Medical Technologies Inc. (the "Issuer" or the "Company").

Trading Symbol: DOCT

Number of Outstanding Listed Securities: 7,913,975

Date: May 6, 2024

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.**
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.**

Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

There has been no development in the business and management is looking into prospective business opportunities.

2. Provide a general overview and discussion of the activities of management.

The Company historically had been manufacturing personal protective equipment (PPE). During the year 2022, in response to the declining demand for face masks, the Company decided to discontinue its mask manufacturing operations.

Subsequently, during the year 2023, the Company dissolved one of its subsidiaries which was involved in the mask manufacturing operations.

The Company is investigating business opportunities in sectors which can offer attractive shareholder return and offer growth opportunities with the infusion of capital.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or strategic plan oil and gas or other reports required under Ontario securities law.

None.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

The Company has discontinued its face mask manufacturing business.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

None.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the dispositions was to a Related Person of the Issuer and provide details of the relationship.

None.

8. Describe the acquisition of new customers or loss of customers.

None.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

None.

10. Report on any employee hiring's, terminations or lay-offs with details of anticipated length of lay-offs.

None.

11. Report on any labour disputes and resolutions of those disputes if applicable.

In May of 2019, the Company received a Human Rights complaint from a former employee and made a preliminary application to dismiss the Claim. In March 2023, a portion of the complaint was dismissed and a settlement of \$15,000 was reached in January of 2024.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

The Company reported a Notice of Claim dated August 22, 2022 commenced in the Provincial Court of British Columbia. The parties to this claim are Alfred & Company Advisors Inc. v. Beyond Medical Technologies Inc. and Bullrun Capital Inc. in the amount of \$35,266. The nature of the claim is for severance and damages for breach of contract. This claim is being contested.

On April 20th, an oral hearing was held before the Small Claims Court where the Company applied to have all of the claims made by Alfred Wong consolidated into one claim and transferred to the B.C. Supreme Court. The judge issued an order

stating the claims will be heard in trial together, however the claims will not be transferred to the B.C. Supreme Court.

A pre-trial conference was scheduled for August 29th, 2023. The Company filed an application to amend the Reply to Claim and Counterclaim that was to be heard on October 23, 2023.

On October 23rd, the Defendants attended an application hearing seeking leave from the court to file the amended Reply's to Claim and Counterclaim. The court adjourned the matter to the Judicial Case Manager to schedule a 15-minute pre-trial conference with Judge Raven to clarify her order with respect to filing the amended Reply to Claim and whether to grant an extension for filing the amended pleadings.

A pre-trial conference was held on December 15, 2023, in which Judge Raven ordered that the Company is permitted to file the amended Reply's to Claim and Counterclaim. The trial has now been set for four (4) days commencing on April 9, 2024.

The parties attended a three (3) day trial commencing on April 9, 2024 and await the court's decision.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None

14. Provide details of any securities issued and options or warrants granted.

None

Security	Number Issued	Details of Issuance	Use of Proceeds ⁽¹⁾

(1) State aggregate proceeds and intended allocation of proceeds.

15. Provide details of any loans to or by Related Persons.

None

16. Provide details of any changes in directors, officers or committee members.

None

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The Issuer's business involves certain risks and uncertainties that are inherent to the Issuer's industry. Please refer to the "Risks Related to The Business" section of the Issuer's management discussion and analysis for the year ended December 31, 2021, which is available on SEDAR at www.sedarplus.com.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: May 6, 2024

Kulwant Malhi
Name of Director or Senior Officer

"Kulwant Malhi"

Signature

Chairman and CEO

Official Capacity

<i>Issuer Details</i>	For Month End	Date of Report
Name of Issuer		YY/MM/D
Beyond Medical Technologies Inc.	May 6, 2024	2024/05/06
Issuer Address		
Suite 1500 – 1055 West Georgia Street		
City/Province/Postal Code	Issuer Fax No.	Issuer Telephone No.
Vancouver, B.C. V6E 4N7	N/A	(604) 805-4602

FORM 7 – MONTHLY PROGRESS REPORT

Contact Name Kal Malhi	Contact Position Chairman and CEO	Contact Telephone No. (604) 805-4602
Contact Email Address kal@bullruncapital.ca	Web Site Address www.beyondmd.ca	